Reference
Reference TypeLiterature
TitleSeparate effects of the ankylosing spondylitis associated ERAP1 and ERAP2 aminopeptidases determine the influence of their combined phenotype on the HLA-B*27 peptidome.
AuthorsAdrian Martín-Esteban; Alejandro Sanz-Bravo; Pablo Guasp; Eilon Barnea; Arie Admon; José A López de Castro
AffiliationsCentro de Biología Molecular Severo Ochoa (Consejo Superior de Investigaciones Científicas and Universidad Autónoma), Madrid, Spain; Faculty of Biology, Technion - Israel Institute of Technology, Haifa, Israel; Centro de Biología Molecular Severo Ochoa (Consejo Superior de Investigaciones Científicas and Universidad Autónoma), Madrid, Spain. Electronic address: aldecastro@cbm.csic.es.
JournalJ Autoimmun
Year2017
AbstractAnkylosing spondylitis (AS) is an inflammatory disease strongly associated with the Major Histocompatibility Complex class I (MHC-I) allotype HLA-B*27. The endoplasmic reticulum aminopeptidases (ERAP)1 and 2, which trim peptides to their optimal length for MHC-I binding, are also susceptibility factors for this disease. Both highly active ERAP1 variants and ERAP2 expression favor AS, whereas loss-of-function ERAP1 and loss-of-expression ERAP2 variants are protective. Yet, only ERAP1 is in epistasis with HLA-B*27. We addressed two issues concerning the functional interaction of ERAP1 and ERAP2 with the HLA-B*27 peptidome in human cells: 1) distinguishing the effects of ERAP1 from those of ERAP2, and 2) determining the influence of ERAP2 in distinct ERAP1 contexts. Quantitative comparisons of the HLA-B*27:05 peptidomes from cells with various ERAP1/ERAP2 phenotypes were carried out. When cells expressing ERAP2 and either high or low activity ERAP1 variants were compared, increased amounts of nonamers, relative to longer ligands, and decreased amounts of peptides with Ala1, were observed in the more active ERAP1 context. When cells expressing ERAP2 in a low activity ERAP1 context or lacking ERAP2 but expressing a highly active ERAP1 variant were compared, the same effects on peptide length and Ala1, but also significantly lower amounts of peptides with N-terminal basic residues and lower affinity of the peptidome, were observed in the ERAP2-positive context. Thus, ERAP1 and ERAP2 have significant and distinct effects on the HLA-B*27 peptidome, suggesting that both enzymes largely act as separate entities in vivo. This may explain their different patterns of association with AS.
Curation Last Updated2024-12-19 20:11:33
Epitope
Epitope ID520339
Chemical TypeLinear peptide
Linear SequenceKRIGNLQTDL
Source Molecule Nameactin-binding protein homolog ABP-278
Source OrganismHomo sapiens (human)
Starting Position35
Ending Position44
Epitope Reference Details
Epitope Structure DefinesExact Epitope
Epitope NameKRIGNLQTDL
Location of Data in ReferenceTables S1 to S4
In Vivo Processing
Host OrganismHomo sapiens (human)
In Vivo Process
In Vivo Process TypeNo immunization
MHC Ligand Assay
Qualitative MeasurementPositive
Method/Techniquecellular MHC/mass spectrometry
Measurement ofligand presentation
Antigen Presenting Cells
Cell Tissue TypeLymphoid
Cell TypeLymphoblast
Cell Culture ConditionsCell Line / Clone
MHC Allele
MHC Allele NameHLA-B*27:05
MHC Evidence CodeElution with MHC specific antibody
MHC Ligand
Epitope RelationEpitope
Chemical TypeLinear peptide
Linear SequenceKRIGNLQTDL
Source Molecule Nameactin-binding protein homolog ABP-278
Source OrganismHomo sapiens (human)
Starting Position35
Ending Position44
Assay Reference Details
Assay Comments by IEDB CuratorThe epitope was eluted from 15510 cells (ERAP2-, ERAP1 Hap1) and P50 cells (ERAP2+, ERAP1 Hap10).
Location of Assay Data in ReferenceFigures 2, 3, 5, 7, S2, S3, S4, and Supplemental Tables 1, 2, 3, and 4